Adenovirus continues to be an important model system for investigating basic aspects of cell biology. Interactions of several cellular proteins with E1A conserved regions (CR) 1 and 2, and inhibition of apoptosis by E1B proteins are required for oncogenic transformation. CR2 binds RB family members, de-repressing E2F transcription factors, thus activating genes required for cell cycling. E1B-19K is a BCL2 homolog that binds and inactivates proapoptotic BAK and BAX. E1B-55K binds p53, inhibiting its transcriptional activation function. In productively infected cells, E1B-55K and E4orf6 assemble a ubiquitin ligase with cellular proteins Elongins B and C, Cullin 5 and RBX1 that polyubiquitinates p53 and one or more subunits of the MRN complex involved in DNA doublestrand break repair, directing them to proteosomal degradation. E1A CR3 activates viral transcription by interacting with the MED23 Mediator subunit, stimulating preinitiation complex assembly on early viral promoters and probably also the rate at which they initiate transcription. The viral E1B-55K/E4orf6 ubiquitin ligase is also required for efficient viral late protein synthesis in many cell types, but the mechanism is not understood. E1A CR1 binds several chromatin-modifying complexes, but how this contributes to stimulation of cellular DNA synthesis and transformation is not clear. E1A CR4 binds the CtBP corepressor, but the mechanism by which this modulates the frequency of transformation remains to be determined. Clearly, adenovirus has much left to teach us about fundamental cellular processes.
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E1A conserved region 3 activation of early viral gene expression
There are four well-conserved regions (CRs) in the E1A protein sequences of the primate adenoviruses (Kimelman et al., 1985; Schaeper et al., 1998; Avvakumov et al., 2004) . Owing to alternative RNA splicing, CR3 is present only in the larger of the two E1A proteins expressed early during viral infection and in adenovirus transformed cells (Figure 1 ). Mutations in CR3 decrease transcription from the four early viral transcription units from five-to 20-fold (Berk et al., 1979; Jones and Shenk, 1979) . This results in a many log decrease in the ability of the resulting host-range mutants to plaque on HeLa cells as opposed to Ad5-transformed 293 cells that constitutively express E1A and E1B (Harrison et al., 1977) . Recently, it was learned that 293 cells were derived from a neural cell in the complex human embryonic kidney cell culture from which it was derived by transfection with sheared Ad5 DNA (Shaw et al., 2002) . 293 cells are widely used in transfection assays because a large fraction of cells express transfected genes at high level. This is probably because large E1A activates transcription promiscuously from transfected promoters and E1B inhibits apoptosis that is otherwise induced to varying degrees by different transfection procedures.
E1A CR3 functions as a strong activation domain (AD) when tethered to a promoter by fusion to the Gal4 DNA-binding domain (Lillie and Green, 1989; Martin et al., 1990) . This AD function is essential for activation of early viral promoters by the authentic E1A protein (Webster and Ricciardi, 1991) . The wild-type large and small E1A proteins are not sequence-specific DNAbinding proteins. Rather, the large E1A protein associates with the DNA-binding domains of cellular transcription factors that bind to the early adenovirus promoters (Liu and Green, 1994) . Binding is through an B10 amino-acid region at the C-teminus of CR3 that is almost completely conserved between different primate adenoviruses. Unlike the situation with many acidic ADs that are random coil until they encounter their protein targets (Radhakrishnan et al., 1997) , E1A CR3 appears to be a well-folded globular protein domain. The 40 N-terminal amino acids of CR3 that function as an AD contain four cysteines that chelate a Zn þ 2 ion and are essential for AD function (Culp et al., 1988) . Thus, the CR3 AD is a type of Zn-finger, although its structure has not been determined. Substitutions at 12 of the 40 positions severely impair or eliminate AD function (Webster and Ricciardi, 1991) .
At high salt concentration, E1A CR3 was found to bind a single protein in fractions purified from a HeLa nuclear extract that supported activation by E1A CR3 in vitro (Boyer TG et al., 1999) . The sequence of this interacting protein revealed it to be the human ortholog of Caenorhabditis elegans SUR-2, a protein involved in developmental decisions regulated by MAP kinases (Singh and Han, 1995) . Human SUR2 was found to be a subunit of the human Mediator complex (Boyer TG et al., 1999) and is now designated MED23 in the recently adapted uniform nomenclature (Bourbon et al., 2004) . Consequently, as found for all other ADs tested (Lee and Young, 2000; Malik and Roeder, 2000; Myers and Kornberg, 2000) , E1A CR3 binds the Mediator complex. In the case of E1A CR3, the Mediator subunit bound by E1A was identified because MED23 was isolated from other Mediator subunits under the conditions of the affinity chromatography used (Boyer TG et al., 1999) . E1A CR3 makes an unusually salt stable (not disrupted by 2 M KCl) interaction with MED23 that facilitated its purification. About onequarter of the MED23 in a HeLa cell nuclear extract behaves as monomer, the remaining three-quarters being associated with Mediator complexes. No other Mediator subunit has been observed in a form separate from the complete Mediator complex, with the exception of the CDK8-CyclinC-MED12-MED13 complex (Borggrefe et al., 2002) . This fortuitous occurrence of free MED23 simplified its identification as the Mediator subunit with which E1A CR3 interacts.
E1A CR3 binds both free MED23 and the Mediator complex, but only the Mediator complex activated transcription in vitro (Wang et al., 2001) . Identification of the CR3-interacting subunit in the Mediator allowed its function to be tested by isolating cells with a knockout of the Med23 gene (Stevens et al., 2002) . CR3 AD function was eliminated in Med23À/À cells. This is one of the few examples of the complete elimination of AD function by mutation of a Mediator subunit. Other studies have shown partial loss of AD function for specific activators in yeast (Suzuki et al., 1988; Park et al., 2000) , mammalian (Ito et al., 2000) and Drosophila cells as the result of elimination or knockdown of specific Mediator subunits. Significant AD function is retained in these examples, suggesting that alternative activation mechanisms still function in the absence of these Mediator subunits. E1A CR3 may be unusual in this regard because it has evolved the strategy of forming a very stable interaction with one Mediator subunit. Other ADs may function through interactions with more than one Mediator subunit as well as with other coactivators such as histone acetylase (HAT) and chromatinremodeling complexes.
As for ADs in yeast (Kuras and Struhl, 1999; Li et al., 1999b) , E1A CR3 promotes the assembly of transcription preinitiation complexes (PICs) (Roeder, 1998) composed of RNA polymerase II and its general transcription factors (Cantin et al., 2003) . Biochemical experiments using extracts from Med23À/À cells showed that E1A CR3 stimulates PIC assembly through a direct interaction with Mediator (Cantin et al., 2003) , as opposed to a more general function of Mediator in transcription initiation (Mittler et al., 2001; Baek et al., 2002) .
Why did E1A CR3 evolve to interact with MED23 as opposed to other Mediator subunits? A possible answer comes from analysis of the mechanism by which the cellular ELK1 transcription factor activates transcription of the Egr1 gene through an interaction with MED23 (Wang et al., 2005) . Cellular transcription factor ELK1, like E1A CR3, was found also to activate transcription through an interaction with MED23 (Boyer TG et al., 1999; Stevens et al., 2002; Cantin et al., 2003) , although B50 other ADs tested function independently of MED23 (Stevens et al., 2002) . The ELK1 AD is regulated by MAP kinase phosphorylation at specific serines (Shaw and Saxton, 2003; Buchwalter et al., 2004) , ELK1 in vitro binding to Mediator through the MED23 subunit is dependent on its phosphorylation by a MAP kinase, and ELK1 activation is greatly inhibited in Med23À/À cells (Stevens et al., 2002) . The C. elegans transcription factor LIN-1 required for vulvul cell differentiation is an ortholog of ELK1. This is probably why sur-2(med23) was isolated in a screen for Large E1A p300, CBP, p400, TRRAP, hGCN5, PCAF, p21, p27, proteosome RB, p107, p130 MED23 CtBP N C CR1 CR2 CR3 CR4 Figure 1 Cellular proteins bound by conserved regions (CRs) of E1A. CR1 binds to the indicated cellular proteins discussed in the text. Binding to some of these also requires two conserved basic residues at the N-terminus. CR2 binds to the RB protein family. Binding is primarily through the LXCXE-motif in CR2, but residues in CR1 also contribute to binding affinity for some of these. See Frisch and Mymryk (2002) for a discussion of the contributions of each of these regions to binding mutations that inhibit vulval cell differentiation in response to activated RAS (Singh and Han, 1995) : mutation of MED23 probably inhibited activation by LIN-1. ELK1 is one of three members of a small gene family encoding the ternary complex class of ETS-box transcription factors (TCFs). These TCFs bind cooperatively with serum response factor (SRF) to serum response elements (SREs) (Hassler and Richmond, 2001; Shaw and Saxton, 2003; Buchwalter et al., 2004) . The prototypical early response gene Egr1 is regulated by serum growth factors such as PDGF and EGF through several SREs in its upstream control region (Thiel and Cibelli, 2002) . Egr1 induction by serum is greatly reduced in Med23À/À mouse ES cells (Stevens et al., 2002) where ELK1 is the predominant TCF (M Balamotis and AJ Berk, unpublished results). Analysis of Mediator, Pol II, and GTF binding to the Egr1 promoter and coding region in Med23À/À cells in comparison to wild-type cells revealed another aspect of the phospho-ELK1 activation mechanism in addition to stimulation of PIC assembly.
Egr1 is controlled by a number of transcription factors in addition to ELK1. Before induction, the promoter is poised to respond rapidly to MAP kinase signaling. The chromatin in the promoter region has the H3K4 trimethylation characteristic of euchromatin, and SRF and ELK1 are bound to multiple SREs (Wang et al., 2005) . Pol II and the other GTFs are bound to a significant fraction of Egr1 promoters before induction. As expected, chromatin immunoprecipitation assays showed no Pol II in the coding region until serum was added to wild-type cells, and this response was greatly reduced in Med23À/À cells. ELK1 molecules bound to the SREs became phosphorylated within 1 min of serum addition, and there was a large increase in Mediator binding, as expected from the in vitro studies. Also as expected from the in vitro studies, there was an increase in the number of PICs on Egr1 promoters, but the increase was much smaller than the increase in Egr1 transcription and the corresponding amount of Pol II in the coding region. In Med23À/À cells, Mediator did not increase in response to serum, and there was a smaller increase in the number of PICs assembled on the promoter in response to serum, but unlike the situation in wild-type cells, most Pol II remained at the promoter and did not transcribe into the coding region. It retained the salt sensitivity characteristics of a PIC as opposed to that of an elongation complex, as observed at heat shock promoters where Pol II has elongated a short distance before pausing (Lis, 1998) . These results indicate that the MAP-kinase-phosphorylated ELK1-MED23 Mediator subunit interaction stimulates both PIC assembly and the rate of transcription initiation by the complete PIC (Figure 2 ). The Egr1 promoter is essentially poised to transcribe the gene, waiting for the signal from a MAP kinase to activate a late step in initiation. This signal comes through an interaction with the MED23 Mediator subunit.
Perhaps adenovirus E1A CR3 evolved to interact with MED23 because this interaction is mechanistically especially powerful at stimulating the rate of transcription initiation and, more importantly, reinitiation. Currently, there is considerable understanding of the differences in proteins associated with a gene that is transcriptionally off, and one that is on. Condensed, hypoacetylated chromatin structure on the one hand with no Pol II or GTFs bound, and on the other hand acetylated, decondensed chromatin with bound activating transcription factors, Mediator, and PICs. However, it is critical to control not only whether or not a gene will be transcribed but also how frequently. For example, there are vast differences between the transcription rate for a gene encoding an enzyme of intermediary metabolism and the b-globin gene in erythroid precursor cells. Currently, we have very little understanding of how the rate of reinitiation of gene transcription is controlled. This may be the level of control where E1A CR3 acts to stimulate early adenovirus transcription.
E1A is not absolutely required for transcription of the early viral genes (to the consternation of the developers of early adenovirus gene therapy vectors). Each of the early promoters has binding sites for cellular transcription factors that promote a low rate of transcription reinitiation in the absence of E1A (Jones et al., 1988) . This allows the dl312 mutant with a virtually complete deletion of E1A to replicate comparably to wild-type virus at high multiplicity of infection (Shenk et al., 1980) . However, after infection with a single virion, the level of early gene transcription is too low to support viral replication unless E1A CR3 turns up the rate of reinitiation by 5-20-fold, depending on the early viral promoter. Similarly murine adenovirus I, which encodes an E1A with a homolgous CR3 that interacts with murine MED23, requires MED23 for high rate transcription of its early genes at low multiplicity of infection (Fang et al., 2004) .
Considering that E1A stimulates transcription from early viral promoters that have bound cellular transcription factors, it is interesting to recall that the CR3-E1A interaction is extremely salt stable. This finding suggests that CR3 may function in part by holding the Mediator at the promoter following each round of transcription initiation and the required disassembly of the PIC. This mechanism has been suggested to stimulate the rate of transcription reinitiation by the strong VP16 AD (Yudkovsky et al., 2000) . In addition, the studies with ELK1 suggest that an interaction with MED23 stimulates PIC initiation. The E1A CR3-MED23 interaction at early adenovirus promoters may have a similar consequence, resulting in rapid initiation followed by rapid reassembly of the PIC around the tightly tethered Mediator, to greatly enhance the rate of reinitiation from the early viral promoters. One would not expect a cellular AD to make such a stable interaction with Mediator because it would not be reversible and would not allow a decrease in transcription when the transcript reached an appropriate level. In contrast, the strategy for a lytic virus like adenovirus is to transcribe its genes continuously at high rate, where an extremely strong interaction would be favorable. Once again, the strategy of looking to a viral protein for insight into an important aspect of cell biology may prove to be a fruitful one with regard to mechanisms controlling the rate of reinitiation from a promoter.
CRs 1 and 2 together stimulate entry into S phase and passage through the cell cycle
The small E1A protein lacking CR3 is sufficient to drive contact inhibited primary cells into S phase and through the cell cycle (Braithwaite et al., 1983; Spindler et al., 1985; Zerler et al., 1987) . This is probably the main contribution of E1A to oncogenic transformation of primary cells by E1A þ E1B and E1A þ activated (G12V) RAS. This is often referred to as the 'immortalization' function of E1A, since it counters the senescence that otherwise occurs in primary rodent cells after multiple cell cycles. Either E1A CR1 or 2 can drive G 0 cells into S phase, although both are required to drive them through the entire cell cycle into mitosis, and both are required to transform primary cells in cooperation with E1B or activated RAS (Howe et al., 1990; Stein et al., 1990) .
E1A CR2 binds to RB and the RB-related proteins p107 and p130 (Barbeau et al., 1992; Dyson and Harlow, 1992; Cobrinik, 2005) that regulate the E2F family of transcription factors (Nevins et al., 1997; Dyson, 1998; Nevins, 2001; Trimarchi and Lees, 2002; Frolov and Dyson, 2004) . The small E1A proteins displace RB and its family members from the E2Fs by binding through an LxCxE-motif with high affinity to the same 'pocket' domain of the RB proteins bound by the E2Fs (Nevins et al., 1997; Ghosh and Harter, 2003) .
The displacement of RB proteins from E2Fs provides a partial explanation for how small E1A drives G 0 cells into S phase and immortalizes primary cells: Entry into S phase is controlled in part by regulating RB protein repression of E2F transcriptional activation function. E2Fs activate transcription of several genes required for entry into S phase, including the all-important late G 1 and S phase cyclin-dependent kinase CDK2 and cyclins E and A. RB proteins repress E2F activation function by binding multisubunit histone deacetylase complexes and probably other types of transcriptional repressors including Polycomb histone methyltransferases (Zhang and Dean, 2001; Frolov and Dyson, 2004) . In normal cell cycles, RB repression is relieved by its phorphorylation by G 1 CDK-cyclins whose expression and activity are controlled by extracellular signals from mitogens, direct contact with neighboring cells, and intrinsic developmental programs. By removing RB proteins from E2Fs, small E1A bypasses all these regulatory signals. Moreover, senescence results from the expression of CDK inhibitors like INK4s and p21 that inhibit RB family protein phosphorylation by G 1 CDK-cyclins (Stein and Dulic, 1998; Ben-Porath and Weinberg, 2004; Satyanarayana and Rudolph, 2004) . Consequently, small E1A also prevents senescence by displacing RB proteins from E2Fs. However, while E1A CR2 displacement of RB proteins from E2Fs is sufficient to drive G 0 cells into S phase, it is not sufficient to drive cells completely around the cell cycle. Functions performed by CR1 are also required (Howe et al., 1990; Stein et al., 1990; Wang et al., 1993) .
While intense research on the E2Fs and RB proteins and their functions in cell cycle control go a long way in explaining how small E1A CR2 stimulates cell cycling, the mechanism by which E1A CR1 stimulates entry into S phase is much less clear. CR1 binds to several cellular protein complexes involved in chromatin structure control. The protein designated 'p300' was the first cellular protein found to interact with CR1 (Stein et al., 1990; Barbeau et al., 1992; Wang et al., 1993) . It was later found to be a close relative, a paralog, of CBP (CREB-binding protein), also shown to bind to E1A CR1 (Arany et al., 1995) . At B300 kDa, p300 and CBP are thought to be multidomain proteins that activate transcription by associating a HAT activity in one domain with gene-specific transcriptional activators and other HAT coactivators that bind to one or more of the several other CBP/p300 domains (Chan and La Thangue, 2001; Vo and Goodman, 2001; Iyer et al., 2004) . Interactions between CBP/p300 and Pol II and GTFs may contribute to activation. Small E1A binds to a C-terminal domain of CBP. It is a controversial point as to whether E1A binding inhibits the HAT activity of CBP/ p300 (Frisch and Mymryk, 2002) . However, by analogy with the inactivation of critical RB protein functions by E1A binding, it is thought that the interaction of E1A with p300/CBP though CR1 inhibits some critical function of these HATs. This is probably the explanation for E1A CR1's inhibition of transcriptional activity by the SV40 and immmunoglobulin enhancers in transfection assays (Eckner et al., 1994) . However, thus far, there is little understanding of how inhibition of a broadly acting HAT activity promotes entry into S phase.
The same lack of an obvious link to cell cycle control applies to the other chromatin-modifying complexes found to interact with E1A CR1. These include p400 which contains a DNA-helicase domain similar to that in the SWI/SNF family of chromatin-remodeling complexes (Fuchs et al., 2001) . E1A CR1 also binds the HAT PCAF (Lang and Hearing, 2003) , and TRAPP (Deleu et al., 2001; Fuchs et al., 2001; Nikiforov et al., 2002) , a component of three HAT complexes in human cells: the TIP60, hGcn5, and PCAF HAT complexes (Sterner and Berger, 2000) . One might expect inhibition or modification of these chromatin-remodeling complexes to affect gene expression broadly. However, in this regard, it is useful to consider the example of Tra1, the S. cerevisiae homolog of TRAPP. Like TRAPP, Tra1 is a subunit of a multimeric HAT complex, SAGA, which includes the HAT Gcn5 (Sterner and Berger, 2000; Timmers and Tora, 2005) . While Gcn5 HAT activity contributes to the activation of many yeast genes, it is not required for activation of the GAL genes by the much studied yeast activator Gal4. Gal4 activation does require Tra1 and other subunits of SAGA. Rather than influencing histone acetylation at the GAL promoters, the Gal4 interaction with SAGA through Tra1 seems to function by stimulating the binding of Mediator complex (Bhaumik et al., 2004) and TBP (Larschan and Winston, 2001 ) to the GAL promoters. Consequently, E1A CR1 interactions with TRAPP might influence the expression of a more specific set of genes than might be expected from an affect on a HAT. Speculation aside, the question of how E1A CR1 contributes to S phase entry remains as one of the most significant relating to E1A transforming activity. It has been reported that inhibition of p300 expression leads to a marked increase in MYC expression that drives G 0 cells into S phase, consistent with the model that E1A CR1 inhibition of p300 function similarly promotes entry into S phase through activation of MYC expression (Kolli et al., 2001) . However, how inhibition of a coactivator leads to an increase in MYC expression is unclear. It has been suggested that CBP and p300 play an especially important role in activation by transcription factors that control cellular differentiation (Goodman and Smolik, 2000) . Inhibition of CBP/ p300 by E1A CR1 might inhibit differentiation-specific gene expression and the cell cycle exit that accompanies many differentiation programs (Frisch and Mymryk, 2002) .
It seems likely that the mechanisms involved in E1A CR1 modification of CBP/p300 function have their counterpart in non-virus-associated human cancer. Germline mutations of CBP are the cause of Rubenstein-Taybi syndrome associated with a high rate of pediatric malignancies, and somatic mutations in CBP and p300 are associated with human tumors (Goodman and Smolik, 2000; Iyer et al., 2004) .
E1A CR1 probably also contributes to cell cycling by binding the CDK inhibitors (CKIs) p21 (Chattopadhyay et al., 2001 ) and p27 (Mal et al., 1996; Alevizopoulos et al., 1998; Nomura et al., 1998) , preventing them from binding and inhibiting CDK-cyclin complexes. These interactions are expected to promote cell cycling by inhibiting control mechanisms that function through these CKIs. E1A CR1 also interacts with and inhibits components of the proteosome, contributing to p53 stabilization by small E1A . This may also contribute to the activation of cell cycling by CR1.
CR4 interacts with the corepressor CtBP
The conserved C-terminal region of E1A, CR4, functions as both a nuclear localization signal (Lyons et al., 1987) and as another transcriptional regulatory region (Chinnadurai, 2002 (Chinnadurai, , 2004 . As for CR1, 2, and 3, CR4 functions by binding to a cellular transcription regulatory protein, the E1A C-terminal binding protein, CtBP. CtBP is a 48 kDa corepressor that interacts with multiple repressors in vertebrates and Drosophila (Chinnadurai, 2002) . In Drosophila, repressors that bind CtBP are critical to early embryonic development, and the function of these repressors is inhibited in CtBPmutant cells (Nibu et al., 1998; Poortinga et al., 1998) . In vertebrates, there are two closely related CtBPs that interact with multiple repressors (Turner and Crossley, 1998; Brannon et al., 1999; Criqui-Filipe et al., 1999; Furusawa et al., 1999; Postigo and Dean, 1999; Chinnadurai, 2002) . CtBPs inhibit transcription in part by binding to several distinct histone deacetylases (HDACs) (Chinnadurai, 2002) . However, repression at some promoters occurs by HDAC-independent mechanisms since it is not affected by the general HDAC inhibitor trichostatin A. HDAC-independent mechanisms include recruitment of histone methylating Polycomb complex proteins (Meloni et al., 1999; Sewalt et al., 1999; Dahiya et al., 2001; Nielsen et al., 2001; Trimarchi et al., 2001; Vandel et al., 2001; Ogawa et al., 2002; Attwooll et al., 2005) and the subsequent binding of HP1 and other heterochromatin-associated proteins that probably repress transcription by inhibiting promoter access to general transcription factors (Cao and Zhang, 2004; Levine et al., 2004; Lund and van Lohuizen, 2004; Ringrose and Paro, 2004) .
Deletion or point mutation of the CtBP-binding PLDLS-motif in E1A CR4 greatly increases the transforming activity of the small E1A protein in assays with activated RAS (Boyd et al., 1993; Chinnadurai, 2002 Chinnadurai, , 2004 . Three general models have been suggested to account for the inhibition of E1A transforming activity by CtBP binding to CR4 (Chinnadurai, 2002) : (1) By analogy with E1A inhibition of the repressing function of RB proteins, E1A CR4 may derepress cellular genes by sequestering CtBPs from cellular repressors. (2) E1A might repress certain cellular genes specifically by associating with their promoter regions and tethering CtBP. (3) Repression by CtBP might inhibit activation by E1A-p300/CBP complexes associated with certain specific cellular genes. Mutation of the CtBP-binding site would then allow E1A to further activate these cellular genes, resulting in a higher frequency of transformation. It is not yet clear which of these mechanisms inhibit E1A transforming activity by CtBP, or how this interaction participates in the adenovirus lytic cycle.
CtBP, first brought to light through its interaction with E1A, is yet another example of adenovirus revealing a key cellular protein involved in non-viral mechanisms of human oncogenesis (Chinnadurai, 2002 (Chinnadurai, , 2004 . Abnormal WNT signaling is an important component of tumorogenesis in many human tumors (Polakis, 2000) . Mutations in APC and b-catenin lead to elevated nuclear concentrations of b-catenin, which binds to TCF transcription factors, activating transcription of associated genes. In the absence of nuclear b-catenin, CtBP associates with TCFs, repressing transcription of the same genes. The discovery of TCF mutations in human colorectal tumors that delete the C-terminal CtBPbinding region raise the possibility that deregulation of TCF-mediated repression may contribute to tumorogenesis (Duval et al., 2000; Saeki et al., 2001) .
Another connection between CtBP and human cancer involves EVI-1 that is elevated or expressed as a fusion with AML1 in many myeloid leukemias. EVI-1 inhibits induction of genes by TGF-b through Smad transcription factors (Kurokawa et al., 1998) . TGF-b-induced genes, such as the CDK inhibitor p21, inhibit cell proliferation (Shi and Massague, 2003; Massague, 2004) . EVI-1 has been shown to repress these antiproliferation genes through interactions with CtBP (Mitani, 2004) , leading to the suggestion that inhibition of the CtBP-EVI-1 interaction might be a therapeutic strategy for the treatment of this class of myeloid leukemias (Palmer et al., 2001) .
CtBP-interacting protein, CtIP, is another corepressor that links CtBP to several specific repression domains (Chinnadurai, 2002) . BRCA1 binds CtIP through its BRCT repeat domain. Mutations of the BRCT repeat that inhibit CtIP binding are linked to hereditary ovarian and breast cancers (Li et al., 1999a) . CtIP also interacts with RB proteins, and may mediate RB HDAC-independent repression through interactions with CtBP and its link to the PcG Polycomb complex (Dahiya et al., 2001 ). This is the major form of repression of RB-E2F-regulated genes in senescent cells (Narita et al., 2003) . Finally, the transforming activity of one of the Epstein-Barr virus transforming proteins EBNA3C depends on its interaction with CtBP (Touitou et al., 2001 ).
E1B functions inhibit apoptosis induced by E1A
Small E1A alone has very little transforming activity (Ruley, 1983) . This is largely because in the absence of E1B or other inhibitors of apoptosis, the same regions of E1A required for transformation, CR1 and 2, also induce apoptosis (White, 2001; Cuconati and White, 2002) . Small E1A causes stabilization of p53 (Lowe and Ruley, 1993) , probably by induction of a DNA-damage response. Proteosome modification by E1A CR1 also contributes to p53 stabilization . This stabilization of p53 leads to apoptosis unless it is blocked by either E1B-19K or E1B-55K, the two principle proteins encoded in E1B (White and Cipriani, 1990; Debbas and White, 1993; Lowe et al., 1994) . This inhibition of p53 and other proapoptotic pathways is a common event in human tumors (Sherr and McCormick, 2002; Lowe and Sherr, 2003; Harris and Levine, 2005; Packham and Stevenson, 2005) .
As discussed below, in adenovirus-infected and transformed cells, p53 inhibition of cell cycling and induction of apoptosis are blocked by E1B-55K protein.
However, adenovirus infection also stimulates apoptosis by a p53-independent mechanism blocked by the other principle E1B product, E1B-19K. In the absence of E1B-19K, the induction of apoptosis in adenovirus-infected cells results in degradation of both cellular and viral DNA, as well as premature host cell death during the lytic cycle, limiting viral replication (White, 2001; Cuconati and White, 2002) .
Apoptosis is induced in cells infected with an E1B-19K mutant because viral infection induces the proteosomal degradation of the critical antiapoptic BCL-2 family member MCL-1 (Cuconati et al., 2003) . Again, this is probably due to induction of a DNA-damage response by viral infection, since MCL-1 proteosomal degradation also is an early response to DNA damage required for induction of apoptosis in UV-irradiated cells (Nijhawan et al., 2003) . The E1B-19K protein, an antiapoptotic MCL-1 viral mimic, blocks this pathway (Cuconati et al., 2003) .
E1B-19K inhibits apoptosis by sequestering BAK and BAX
E1B-19K is homologous in sequence and function to cellular BCL-2 (Cuconati and White, 2002) . Degradation of MCL-1 as a consequence of E1A expression results in the release and activation of the proapoptotic BCL2-family member BAK, normally bound by MCL-1 in uninfected cells (Cuconati et al., 2003) (Figure 3 ). E1B-19K binds to both BAK and another proapoptotic BCL-2 family member BAX, preventing them from cooligomerizing and forming pores in the outer mitochondrial membrane. In the absence of E1B-19K, formation of such BAK-BAX pores in mitochondria of infected cells releases apoptogenic proteins such as cytochrome c and Smac/DIABOLO (White, 2001; Cuconati and White, 2002) . These and other apoptogenic proteins released from mitochondria lead to the activation of caspase-9 and -3 and the ensuing apoptosis program (Cory et al., 2003) . However, the pathway is blocked in wild-type virus-infected cells by the sequestration of activated BAK and BAX by E1B-19K binding (White, 2001 ).
E1B-55K has several activities that inhibit p53 function
E1B-55K can also cooperate with small E1A to transform mammalian cells. p53 first came to attention because it is bound by two DNA virus transforming proteins: SV40 T-antigen (Lane and Crawford, 1979) and adenovirus E1B-55K (Sarnow et al., 1982) . For more than 20 years it has been observed that in Ad5-transformed cells, p53 is bound to E1B-55K in large subcellular structures in the cytoplasm near the nucleus (Zantema et al., 1985) . Recently, it was recognized (Liu et al., 2005) that these structures are aggresomes, a subcellular structure formed at the microtubule organizing center in response to the accumulation of misfolded proteins (Kopito, 2000; Garcia-Mata et al., 2002) (Figure 4) . The sequestration alone is not sufficient to inhibit p53's function as a transcription factor, since an E1B-55K mutant R443 binds p53 in these virus-induced aggresomes similar to wt E1B-55K (Liu Y and AJ Berk, unpublished results) , but cannot repress activation by p53 (Yew and Berk, 1992) . Apparently, sufficient p53 remains in the nucleus to activate transcription.
However, in cells expressing wt E1B-55K, such as cells transformed by E1A þ E1B, E1B-55K inhibits transcriptional activation by nuclear p53 (Yew and Berk, 1992; Teodoro and Branton, 1997) . This is because E1B-55K binds with high affinity and specificity to the p53 AD, probably sterically blocking interactions with coactivators and tethering a strong repression domain to p53 (Yew et al., 1994; Berk, 1998, 1999) . The repression domain function of E1B-55K was demonstrated in experiments with Gal4 DNA-binding domain fusions (Yew et al., 1994) . The R443 mutant is defective in this repression domain activity, as is a mutant that prevents phosphorylation at the E1B-55K C-terminus (Teodoro and Branton, 1997). These mutants are also defective for inhibition of transcriptional activation by p53 even though they bind to p53 like wt E1B-55K. They are also defective in transformation with E1A. These observations lead to the model that E1B-55K inhibits activation by p53 by binding a repression domain to it, converting the activator into a repressor of p53-activated genes ( Figure 5 ). The stabilization of p53 by E1B-55K (in the absence of E4orf6) (Levine, 1990 ) causes a dramatic increase in p53 concentration. Also, p53 bound to E1B-55K has a 10-fold higher affinity for its binding site than free p53 (Martin and Berk, 1998) . This increased concentration and binding affinity presumably turn the p53-E1B-55K complex in the nuclei of transformed cells into a potent repressor of genes with p53-binding sites.
Repression by E1B-55K in vitro acts on so-called 'basal' transcription, observed when the GTFs are purified away from Mediator. However, this nonchromatin-based repression depends on a cellular corepressor that has so far eluded identification (Martin and Berk, 1998) . E1B-55K also interacts with the mSin3A/HDAC 1 complex (Punga and Akusjarvi, 2000) . Consequently, it may also repress through a mechanism involving an HDAC. However, repression by a Gal4-DBD-E1B-55K fusion in a transient transfection assay was not inhibited by trichostatin A (S Sikora and AJ Berk, unpublished result), suggesting that E1B-55K primarily utilizes a mechanism of repression that does not rely on histone deacetylation. E1B-55K also inhibits the acetylation of p53 by PCAF required for high-affinity p53 DNA binding, contributing to p53 inhibition by yet another mechanism (Liu et al., 2000) .
E1B-55K function is much better understood in adenovirus-infected cells than in transformed cells. In infected cells, the vast majority of E1B-55K is found in a complex with the viral protein encoded in the fourth open reading frame in the E4 transcription unit, E4orf6 (Sarnow et al., 1984) . E4orf6 is not found in most Ad5-transformed cells because the right end of the viral genome encoding it is not integrated in most Ad5-transformed cells that contain only the E1A and E1B transcription units (Shenk, 2001 ). The E1B-55K/E4orf6 complex in infected cells is assembled with several cellular proteins into a high molecular weight ubiquitin ligase complex with Elongins B and C, Cullin5, and Rbx-1 (Querido et al., 2001; Harada et al., 2002) . E1B-55K is the substrate recognition subunit of this complex, while E4orf6 binds Elongin C (Blanchette et al., 2004) . In effect, the virus commandeers the cellular Cullin5-based ubiquitin ligase complexes, giving them viral substrate-recognition subunits (Figure 6 ).
There are two known substrates for the E1B-55K/ E4orf6 ubiquitin ligase complex: p53, which has been shown to be a substrate in vitro (Querido et al., 2001; Harada et al., 2002) , and the cellular MRN complex (Stracker et al., 2002) . The MRN complex is so named because it is composed of three proteins known from genetic studies to be involved in DNA double-strand break repair: MRE11, RAD50, and NBS1. It binds to the ends of broken DNA molecules, modifying them with an endogenous exonuclease activity to prepare them for nonhomologous end joining (NHEJ) through interactions with multiple DNA repair proteins (D'Amours and Jackson, 2002; Petrini and Stracker, 2003) . These include the ATM and ATR kinases that activate the global cellular DNA-damage response (Carson et al., 2003) . Although none of the MRN subunits have yet been shown to be polyubiquitinated by the viral E1B-55K/E4orf6 complex, MRN subunits are degraded in adenovirus-infected cells dependent on both E1B-55K and E4orf6, making it very likely that MRN is a substrate of the viral ubiquitin ligase (Stracker et al., 2002) .
When MRN activity is not inactivated as during infection with an E4-deletion mutant, the MRN complex treats the ends of the linear adenovirus DNA like a DNA double-strand break. Viral DNA becomes ligated into long concatomers of randomly oriented genomes by the cellular NHEJ proteins (Weiden and Ginsberg, 1994; Boyer J et al., 1999; Evans and Hearing, 2003; Shepard and Ornelles, 2004) . Even when NHEJ is blocked by mutations in NHEJ proteins, the MRN Cullin-based ubiquitin ligases and their relationship to the adenovirus E1B-55K/E4orf6 ubiquitin ligase complex. The structure of the multisubunit SCF complex (diagrammed at the top) is the best understood of the Cullin-based ubiquitin ligases (Zheng et al., 2002) . The complex polyubiquitinates the p27 CDK inhibitor that is bound by the Cks1 and Skp2 subunits. The VHL ubiquitin ligase is proposed to have a similar structure with Elongin B and C bridging VHL and Cullin2 (Stebbins et al., 1999) . In both complexes, the ring-finger protein Rbx1 is bound by the C-terminal domain of the Cullin where it interacts with a charged E2 that transfers its ubiquitin to the substrate (red). The E1B-55K-E4orf6-Elongin BC-Cullin5-Rbx1 complex formed in infected cells is thought to have a similar general structure to the SCF and VHL ubiquitin ligase complexes with E4orf6 interacting with Elongin C (Blanchette et al., 2004) and E1B-55K. p53 is bound by both E1B-55K at the p53 N-terminus and E4orf6 at p53 C-terminus (Dobner et al., 1996) . Figure adapted from Querido et al. (2001) p53 p53
55K
Figure 5 Transcriptional activation by p53 is blocked by E1B-55K. E1B-55K binding does not displace p53 from its DNAbinding sites. Instead, E1B-55K increases p53 stability by binding to the same region in the AD bound by the p53 ubiquitin ligase MDM2. E1B-55K binding also increases the affinity of p53 for p53-DNA binding sites. E1B-55K also exhibits strong transcriptional repression domain activity. As a result, the highly regulated p53 activator is converted into a constitutive repressor of genes with p53-binding sites complex still interferes with viral DNA replication (which initiates at the termini) in E4-deletion mutantinfected cells (Evans and Hearing, 2003; Shepard and Ornelles, 2004) . Clearly, it is important for adenovirus to inactivate the MRN complex as rapidly as possible after viral infection. Interestingly, the induction of aggresomes in infected cells by E1B-55K greatly increases the rate of MRN degradation (Liu et al., 2005) . This result demonstrated that sequestration of a polyubiquitinated protein into an aggresome increases the rate of its proteosomal degradation. Aggresomes are observed in many degenerative diseases, such as Parkinson's and Huntington's diseases and alcoholic liver disease (Tran and Miller, 1999; Taylor et al., 2002; Forman et al., 2004) . The results with E1B-55K in adenovirus-infected cells indicate that aggresome formation is a protective response that increases the rate of degradation of polyubiquitinated proteins. In infected cells, MRN first interacts with E4orf3 in PML nuclear domains of altered morphology (Carvalho et al., 1995; Doucas et al., 1996; Evans and Hearing, 2005) . E1B-55K then interacts with MRN in these modified PML nuclear bodies. Complexes of MRN with E1B-55K, E4orf6, and E4orf3 are finally exported out of the nucleus to aggresomes where MRN subunits are rapidly degraded (Liu et al., 2005) . Adenovirus exploits the cellular aggresome pathway to accelerate the inactivation of MRN complexes, first by sequestration into the cytoplasm, and then through accelerated proteosomal degradation.
One of the prominent phenotypes of both E1B-55K and E4orf6 mutants is a defect in the expression of late viral genes encoding virion structural proteins (Flint and Gonzalez, 2003) . For E1B-55K mutants, viral DNA replication is normal in p53-minus cells (Harada and Berk, 1999) even though MRN subunits are not degraded. This is because E4orf3 and E4orf6 proteins also inhibit MRN function (Boyer J et al., 1999; Shepard and Ornelles, 2004; Evans and Hearing, 2005) . In HeLa and KB cells, the defect in E1B-55K mutant late viral protein synthesis results from a defect in export of late viral mRNAs from the nucleus to the cytoplasm (Babiss et al., 1985; Pilder et al., 1986; Leppard and Shenk, 1989; O'Shea et al., 2004) . In HeLa cells infected with wild-type Ad5, E1B-55K simultaneously stimulates late viral mRNA nuclear export and inhibits host cell mRNA export (Beltz and Flint, 1979) . However, in some cell types, the defect in nuclear export is modest; rather, there is a large defect in the translation of late viral mRNAs (Harada and Berk, 1999) .
As yet, there is no clear connection between the known functions of E1B-55K and E4orf6 and their influence on late viral mRNA export (Flint and Gonzalez, 2003) . There is significant interest in this area since it has been suggested that an E1B-55K mutant may be useful as an oncolytic therapeutic agent (Bischoff et al., 1996) . This strategy is based on the idea that an E1B-55K mutant would be unable to replicate in p53-plus normal cells because of its inability to inhibit p53 function, but that it would be able to replicate in most human tumor cells because of inactivation of p53 or p53 pathways in most human tumors (Sherr and McCormick, 2002) . However, there is considerable variation in the ability of an E1B-55K deletion mutant to replicate in different human tumor cells, correlating with the dependence of late viral protein synthesis on E1B-55K function in the different tumor cells (Harada and Berk, 1999; O'Shea et al., 2004) . Understanding the mechanism by which E1B-55K stimulates late viral protein synthesis might allow prediction of which tumors would be candidates for treatment with an E1B-55K mutant, and might allow the design of more specific E1B-55K mutants defective in the inactivation of p53 but still active in the ability to stimulate late viral protein synthesis.
The observations that absence of E1B-55K inhibits late viral mRNA nuclear export in some cells and mRNA translation in others raise the possibility that the E1B-55K/E4orf6 complex may affect an mRNP protein involved in both mRNP export and translation. Cellular RNA-binding proteins are known that participate in both nuclear export and translation regulation, such as components of the exon junction complex (EJC) that interact with mRNP transporters in the nucleus and participate in nonsense-mediated decay in the cytoplasm (Maquat, 2004; Tange et al., 2004) . Since most E1B-55K and E4orf6 in infected cells are associated with the viral Cullin5 ubiquitin ligase complex (Harada et al., 2002) , an obvious model is that the complex has at least one other cellular substrate in addition to p53 and MRN, an mRNP protein whose degradation inhibits most cellular mRNA nuclear export, stimulating export and translation of late viral mRNAs. However, thus far, no additional substrates have been identified.
Adenovirus appears to employ additional mechanisms for inactivating p53 function besides those involving E1B-55K. Infection with mutants in E1B-55K and E4orf6, which cannot cause the degradation of p53, result in the stabilization and accumulation of p53 with the post-translational modifications of activated p53, but p53-responsive genes are not induced (Hobom and Dobbelstein, 2004) . Their transcription apparently is blocked at a step subsequent to p53 activation.
Overview
Adenovirus early proteins prepare the host cell for maximal production of progeny virions. To do this, they bind to and alter the activities of critical cellular regulators of gene expression, cell cycling, and apoptosis. Mechanisms of action are now fairly well understood for E1A CR3 and CR2, E1B-19K, and E1B-55K's part in p53 degradation following viral infection. E1A CR3 activates transcription by interacting with the MED23 subunit of the Mediator of transcription complex. This stimulates PIC assembly, and may also increase the rate at which PICs initiate transcription. The net effect results in an increase in the rate of reinitiation at viral early promoters. E1A CR2 activates cell cycling by displacing RB family proteins from E2F family transcription factors. Since the RB proteins appear to be the bridge between E2Fs and chromatin-based repression mechanisms, this derepresses genes critical to cell cycling. These include G 1 and S phase cyclins and CDKs and proteins directly involved in DNA replication and deoxynucleotide synthesis, promoting entry into S phase.
E1B-19K is effectively a viral BCL2 family member that replaces MCL-1 as an inhibitor of BAK when MCL-1 is degraded via a DNA-damage response induced by viral infection. E1B-19K also binds to BAX, inhibiting the formation of BAK-BAX oligomers that otherwise form pores in the outer mitochondrial membrane, releasing activators of apoptotic caspases.
During viral infection, E1B-55K and E4orf6 assemble a Cullin5-based ubiquitin ligase that polyubiquitinates p53 and a subunit of the MRN complex critical to DNA double-strand break repair.
Much less is understood about how the intriguing activities of E1A CR1 and CR4 influence cell cycling and how E1B-55K inhibits p53 function in the absence of E4orf6. E1A CR1 alone stimulates cells to enter S phase and is required along with CR2 for stable transformation. The discoveries that CR1 binds HAT and chromatin-remodeling complexes suggests that it functions by influencing transcription of host cell cycle regulatory genes. Does it do this by sequestering and inactivating these chromatin-modifying complexes in analogy with how it inactivates RB family proteins? Or does it somehow localize the chromatin-modifying complexes to specific cellular genes, activating their expression? Most importantly, what critical genes are regulated? The answer may lie in an extensive microarray analysis of cellular gene expression early after adenovirus infection (Zhao et al., 2003) . Remarkably, this analysis revealed changes in very few cell cycle genes, perhaps because the cells being studied were rapidly proliferating so that cell cycle genes were induced before infection. The question remains: what cell cycle genes regulated by CR1 cooperate with the E2F-regulated genes derepressed by CR2 to fulfill E1A's part in transformation?
CR4 inhibits transformation by binding the CtBP corepressor that in turn binds HDAC and polycomb complexes. Which of the several mechanisms discussed account for CR4's repression of cell cycle activation by E1A CR1 and CR2? Once again, what are the critical cell cycle genes whose expression is altered by CR4 binding to CtBP?
E1B-55K is a substrate-binding subunit of the viral ubiqutin ligase that marks p53 and one or more subunits of the MRN complex for proteosomal degradation. However, E1B-55K alone also inhibits p53 function as a transcriptional activator by tethering a repression domain to it. E1B-55K repression domain function requires an as yet unidentified cellular corepressor. Is there a mechanistic link between E1B-55Ks function in a ubiqutin ligase and its transcription repression domain function? How do E1B-55K and E4orf6 stimulate viral late mRNA export and translation? These questions remind us that although adenovirus has taught us much, it has much left to teach us.
For additional references in these areas and alternative points of view, please see other recent reviews of the topics considered here (Gallimore and Turnell, 2001; White, 2001; Ben-Israel and Kleinberger, 2002; Chinnadurai, 2002 Chinnadurai, , 2004 Frisch and Mymryk, 2002; Sang et al., 2002; Brockmann and Esche, 2003; Flint and Gonzalez, 2003; Helt and Galloway, 2003; Endter and Dobner, 2004; Williams et al., 2004) .
